453 related articles for article (PubMed ID: 24549060)
21. The value of fixed rasburicase dosing versus weight-based dosing in the treatment and prevention of tumor lysis syndrome.
Boutin A; Blackman A; O'Sullivan DM; Forcello N
J Oncol Pharm Pract; 2019 Apr; 25(3):577-583. PubMed ID: 29320954
[TBL] [Abstract][Full Text] [Related]
22. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
Vadhan-Raj S; Fayad LE; Fanale MA; Pro B; Rodriguez A; Hagemeister FB; Bueso-Ramos CE; Zhou X; McLaughlin PW; Fowler N; Shah J; Orlowski RZ; Samaniego F; Wang M; Cortes JE; Younes A; Kwak LW; Sarlis NJ; Romaguera JE
Ann Oncol; 2012 Jun; 23(6):1640-5. PubMed ID: 22015451
[TBL] [Abstract][Full Text] [Related]
23. Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
Kennedy LD; Ajiboye VO
J Oncol Pharm Pract; 2010 Sep; 16(3):205-13. PubMed ID: 19923162
[TBL] [Abstract][Full Text] [Related]
24. Rasburicase dose optimization for tumor lysis syndrome management in a network of community oncology practices.
Gilmore S; Carroll M; Koselke E; Hough S
J Oncol Pharm Pract; 2024 Jul; 30(5):867-872. PubMed ID: 37563922
[TBL] [Abstract][Full Text] [Related]
25. Treatment of tumor lysis syndrome in children with leukemia/lymphoma in resource-limited settings-Efficacy of a fixed low-dose rasburicase.
Gopakumar KG; Thankamony P; Seetharam S; P K
Pediatr Hematol Oncol; 2017 May; 34(4):206-211. PubMed ID: 28872997
[TBL] [Abstract][Full Text] [Related]
26. Utilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification.
Khalighi PR; Martens KL; White AA; Li S; Silgard E; Frieze D; Garcia DA; Li A
J Oncol Pharm Pract; 2020 Apr; 26(3):529-535. PubMed ID: 31167612
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.
Coiffier B; Mounier N; Bologna S; Fermé C; Tilly H; Sonet A; Christian B; Casasnovas O; Jourdan E; Belhadj K; Herbrecht R;
J Clin Oncol; 2003 Dec; 21(23):4402-6. PubMed ID: 14581437
[TBL] [Abstract][Full Text] [Related]
28. Rasburicase for the treatment and prevention of hyperuricemia.
Yim BT; Sims-McCallum RP; Chong PH
Ann Pharmacother; 2003; 37(7-8):1047-54. PubMed ID: 12841818
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer.
Reeves DJ; Bestul DJ
Pharmacotherapy; 2008 Jun; 28(6):685-90. PubMed ID: 18503395
[TBL] [Abstract][Full Text] [Related]
30. [Rasburicase therapy may cause hydrogen peroxide shock].
Góth L
Orv Hetil; 2008 Aug; 149(34):1587-90. PubMed ID: 18708312
[TBL] [Abstract][Full Text] [Related]
31. Rasburicase and tumor lysis syndrome: lower dosage, consideration of indications, and hyperhydration.
Darmon M; Guichard I; Vincent F
J Clin Oncol; 2011 Jan; 29(3):e67-8; author reply e69. PubMed ID: 21149649
[No Abstract] [Full Text] [Related]
32. A retrospective observational study of a low fixed-dose rasburicase protocol for the treatment of tumor lysis syndrome in adults.
Hossain S; Naber M; Yacobucci MJ
J Oncol Pharm Pract; 2022 Sep; 28(6):1326-1331. PubMed ID: 34115548
[TBL] [Abstract][Full Text] [Related]
33. More to rasburicase than uric Acid.
Patel S; Le AN
Pharmacotherapy; 2013 Sep; 33(9):e177. PubMed ID: 23744455
[No Abstract] [Full Text] [Related]
34. Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind-randomized study.
De Angelis S; Noce A; Di Renzo L; Cianci R; Naticchia A; Giarrizzo GF; Giordano F; Tozzo C; Splendiani G; De Lorenzo A
Eur Rev Med Pharmacol Sci; 2007; 11(3):179-84. PubMed ID: 17970234
[TBL] [Abstract][Full Text] [Related]
35. A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome.
Kikuchi A; Kigasawa H; Tsurusawa M; Kawa K; Kikuta A; Tsuchida M; Nagatoshi Y; Asami K; Horibe K; Makimoto A; Tsukimoto I
Int J Hematol; 2009 Nov; 90(4):492-500. PubMed ID: 19701676
[TBL] [Abstract][Full Text] [Related]
36. Treatment of impending tumor lysis with single-dose rasburicase.
Lee AC; Li CH; So KT; Chan R
Ann Pharmacother; 2003 Nov; 37(11):1614-7. PubMed ID: 14565793
[TBL] [Abstract][Full Text] [Related]
37. Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies.
Yaman S; Başcı S; Turan G; Ulu BU; Yiğenoğlu TN; Dal MS; Kızıl Çakar M; Altuntaş F
Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):e71-e76. PubMed ID: 34565690
[TBL] [Abstract][Full Text] [Related]
38. Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia.
Martens KL; Khalighi PR; Li S; White AA; Silgard E; Frieze D; Estey E; Garcia DA; Hingorani S; Li A
Leuk Res; 2020 Feb; 89():106298. PubMed ID: 31945598
[TBL] [Abstract][Full Text] [Related]
39. Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy.
Hutcherson DA; Gammon DC; Bhatt MS; Faneuf M
Pharmacotherapy; 2006 Feb; 26(2):242-7. PubMed ID: 16466328
[TBL] [Abstract][Full Text] [Related]
40. Single dose of rasburicase for treatment of hyperuricemia in acute kidney injury: a report of 3 cases.
Hooman N; Otukesh H
Iran J Kidney Dis; 2011 Mar; 5(2):130-2. PubMed ID: 21368393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
